bioMérieux S.A. (OTCMKTS:BMXMF – Get Free Report) saw a large decline in short interest during the month of September. As of September 15th, there was short interest totalling 165,200 shares, a decline of 26.8% from the August 31st total of 225,800 shares. Based on an average daily trading volume, of 100 shares, the days-to-cover ratio is currently 1,652.0 days.
Analyst Upgrades and Downgrades
Separately, UBS Group upgraded shares of bioMérieux to a “strong-buy” rating in a report on Thursday, August 22nd.
View Our Latest Analysis on bioMérieux
bioMérieux Stock Performance
About bioMérieux
bioMérieux SA develops and produces in vitro diagnostic solutions for the diagnosis of infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers systems that use biological samples, such as blood, saliva, urine, etc. for the diagnosis of infectious diseases, including bacterial infections, parasitic infections, and viral infections; and microbiological control of production or the production environment primarily for food, pharmaceutical, and cosmetic industries.
Featured Articles
- Five stocks we like better than bioMérieux
- Low PE Growth Stocks: Unlocking Investment Opportunities
- CarMax’s Impressive Rally: What Investors Should Watch Next
- 3 Stocks to Consider Buying in October
- MarketBeat Week in Review – 9/23 – 9/27
- Consumer Staples Stocks, Explained
- Wake Up to This Biotech Stock That Still Has Big Potential Upside
Receive News & Ratings for bioMérieux Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bioMérieux and related companies with MarketBeat.com's FREE daily email newsletter.